The evolution of haloperidol (Haldol) research directed toward the concept of adequate, individualized dosages (AID) has been stimulated by many factors, the most important of which has been a thorough review of the experiences of a large number of innovative and concerned physicians throughout the world. Since 1958, these worldwide efforts have included both individual and organized investigations for that dosage and regimen of haloperidol which would afford optimal therapeutic response to the majority of psychotic patients under a physician's care or within a specific study census.
In this short review, it would be impossible to list or describe the multitude of clinical experiences reported since haloperidol's introduction in 1958. The studies highlighted the necessity for individualized treatment of all psychotic patients and demonstrated that for maximal therapeutic control a broadened therapeutic dosage range was necessary. These worldwide experiences, which validate the AID premise, are described at length in a summary issued by McNeil Laboratories (1975) .
Early studies in the United States and Europe were encumbered by rigidly controlled dosage requirements as well as inefficient titration rates with minimal increments of haloperidol. Only a narrow range of doses was given to all psychotic patients, regardless of floridity of presenting symptoms or individual response. Thus, in the initial product labelling, the prescribing physician was held to a minimum approved initial dose of 0.5 mg three times a day and a minimum increment and rate of titration: add 0.5 mg once daily every seventh day until a maximum dose of 15 mg per day was reached. Such a regimen required physician 'patience' and yet, miraculously, afforded approximately 50% of the patients some therapeutic control. However, physicians with experience in the use of haloperidol soon questioned the rationale of the 15 mg daily ceiling, which required a long period for control of symptoms and resulted in haloperidol's being classified as having a therapeutic profile similar to that of other neuroleptic agents available at the time. In spite of this misdirection, physicians observed early that maxima and regimens had to be adapted to each patient for optimal control. In England, Danik & Goverdham (1962) in a study of patients in Leicester, concluded that 'the degree of dosage tolerance varies a great deal from one patient to another and therefore all patients should not be treated in a routine manner'. A similar observation was made by Oldham & Bott (1971) , in a study at Guy's Hospital in London. Working with the parenteral form of haloperidol in acutely excited patients, these investigators recorded the necessity for a broadened individualized dosage range and regimen of haloperidol (20 mg to 79 mg daily) for optimal control of the patients.
A review of all European experience prior to the approved use of haloperidol in the United States emphatically substantiates the assertion that haloperidol dosage and regimens must be individualized to obtain an efficient antipsychotic effect in psychotic patients. In the United States, during the investigational phases and immediately after government approval of haloperidol, there was a broadening of its therapeutic range and individualization of regimens by investigators.
Goldman (1967) stated in the proceedings of the International Psychopharmacology Symposium on Haloperidol: 'It's important that we don't disregard doses over 16 mg since such doses, including those greater than 32 mg, produced improvement. This improvement was undoubtedly in patients whose illness was of a greater severity, who needed a higher dose of medication and, therefore, who exhibited a higher proportion of side effects. We have to recognize that when higher doses are necessary, we will get a higher proportion of side effects that will have to be tolerated until drugs become available that generate fewer side effects. This doesn't mean that the maximum dosage should be the level at which the side effects curve crosses the improvement curve. If we choose this dose as the cut-off point, we'll fail to help a lot of patients. We should not be too afraid of side effects that we can manage.' Similar validation of the AID principle is apparent from a review of all experience in the United States, where studies also proved the value of haloperidol treatment regimen directed by close observation of individual patient behaviour and safety. Man (1973) utilized haloperidol in a mean high daily dose of 29.4 mg (range 2-145 mg daily) in a study that extended over two years. In discharging 59 of 64 chronic and acute psychotic patients from the hospital, Man concluded that the higher the dose, the greater the risk of side-effects but, most significantly, the greater the chance the patient would improve. Only 17% of these patients returned to the hospital over the next two years. Follow up of all those continuing haloperidol treatment (average maintenance dose 2.8 mg per day) revealed no abnormalities in any organ systems. Similarly, Howard & Schmidt (1973) , using the principles of AID, were able to effect sufficient behavioural improvement among backward incorrigible patients to place more than half in community facilities, thus affording meaningful respite from chronic institutionalization and a saving to the state of approximately $150 000 a year. Close analysis of this study provided insight into the increasing success of the AID programmes. This success could be attributed directly to the innovative, concerned physician with thorough knowledge of his patients, monitoring his personnel and using individualized drug regimens over a broad therapeutic range, while stressing efficient recognition and management of side-effects. Perhaps the most important aspect of the success of this programme was the physician's directing use of the drug toward ambulatory and productive activity and discharge rather than to somnolent states requiring continued long-term state hospitalization and nursing. The physician and his art remain the most important factor in the success of a rehabilitative programme in both acute and longterm chronic patients.
Howard contributed further to our knowledge of the psychopathology of backward patients in his 'Somatic Profiles in Chronic Schizophrenia' (Howard 1976) by pointing out the need to examine all patients for somatic disease which can cause psychotic symptoms (thyroid, glucose and folic acid disorders). These unrecognized somatic problems, as well as underdosing with antipsychotic drugs, have resulted in patients being classified as refractory to treatment.
Recent innovative studies by Palestine (1973) , Reschke (1974) Optimal control of psychotic behaviour has been obtained in minutes and hours without undue sedation. This allows outpatient treatment or short-term inpatient treatment with early psychosocialization and minimal nursing and other supervision. These studies have also produced psychometric documentation of haloperidol's ability to change thought and mood psychopathology in the acute titration period (three to six hours). This rapid titration technique, based on AID principles, has received attention in the USA for many reasons, one of which is a recent Supreme Court ruling that proscribes long-term custodial hospitalization of the mentally ill without treatment. Government and private insurance fundings require control and disposition of mentally ill patients within a two-to threeweek ultilization period. This can only be accomplished by an efficient, diligent and innovative concentration of treatment based on close observation of individual patient responses. A means to achieve this in large numbers of patients is individualized treatment, titration of haloperidol parenterally to optimal control of behaviour, and switchover to haloperidol orally with continued control and concomitant prevention of undesirable side-effects. The final disposition of the patient to a productive environment outside the hospital can be achieved within this two-to three-week period. Such techniques have been studied by Donlon & Tupin (1974) and Anderson et al. (1976) and represent the primary thrust of our present research programme.
Efficient return of the psychotic patient to productive capacity in his domestic environment does much to dissipate the stigma of mental disease that is so prevalent. When such return is achieved routinely, long-term hospitalization will be passe, and the disease state will not be compounded by this treatment method per se. Treatment will be sought and not hidden from, nor run from, nor decried, nor disguised by patients and their families.
AID studies have also generated useful information on the nature and management of extra-pyramidal side-effects and sedation. A particularly interesting finding has been the reduced incidence of extrapyramidal reactions in patients receiving haloperidol in the upper range of doses currently recommended. Hollister (1975) , Donlon & Stenson (1976), and Snyder et al. (1974) attribute this decrease to increased anticholinergic activity of the drug at these doses. It has also become evident from reports such as those by Kiloh et al. (1973) and Thornton & Thornton (1975) that in patients receiving long-term treatment with neuroleptic agents continued dopamine blockade is not solely responsible for the development of tardive dyskinesia. The continued blockade of the cholinergic system by the sedative neuroleptic agents (chlorpromazine and thioridazine), together with injudicious and prolonged use of anti-parkinsonism agents, may decrease the threshold for tardive dyskinesia, predisposing the patient to its development.
Singh & Smith (1973a, b), like Goldman in 1967, suggested that the primary determinant for therapy should be therapeutic response, not the development of extrapyramidal reactions, because these are often self-limited, probably by homeostatic mechanism. In addition, Singh (Singh & Smith 1 973a, b) suggests that the routine use of anti-parkinsonian drugs should be avoided since they may reduce therapeutic efficacy. Orlov et al. (1971) also recommend that their long-term use be avoided because the majority of dystonic and other extrapyramidal phenomena are self-limiting. Continued use of such agents, moreover, may mask an early tardive dyskinesia which is still readily reversible. Accordingly, Schiele et al. (1973) recommend drug holidays and drug withdrawals to prevent the long-term effects and verify the need for continuing use of antipsychotic drugs.
Certainly the foregoing facts concerning the safe use of drugs over long periods are mandatory information that can only be applied successfully through thorough and continued knowledge of each patient's condition.
Finally, the AID principle has also gained support from pharmacokinetics studies that document a 10-30-fold variation in serum concentration of haloperidol. Forsman & Ohman (1974) , who reported a 10-fold variation in its steady state concentration in I I different patients, suggested that this may explain unsuccessful therapeutic results and unexpected side-effects of the drug. Related data obtained in our Research Division show that the therapeutic response does not necessarily correlate directly with serum concentration of haloperidol, suggesting that it is concentrated elsewhere in the body, perhaps at receptor sites in the brain where its therapeutic effects are exerted. The AID rapid tranquillization studies document both psychometrically and audiovisually the therapeutic lysis of psychosis, with return to reality in 4-24 hours. In the future, study of serum concentrations of haloperidol determined at the time of optimal therapeutic control would add much to our understanding of basic psychopharmacokinetics and clinical behaviour.
This perspective review concludes with a prospective preview of the haloperidol AID programme. The day may soon be here when physicians can provide rapid and efficient shortand long-term control of psychotic disorders, much as they now provide such control for infective, cardiovascular and respiratory tract disease. Efficient management developed by the psychiatric disciplines will be taught to all physicians and it is not far-fetched to prognosticate a 1985 phone call to the primary physician -'Please give me an appointment to check my infected sinuses, my high blood pressure and my psychotic disorder.' 
DISCUSSION
Dr P E Garfinkel (Torontto) said that there was currently much interest in the monitoring of plasma levels of tricyclic agents in the study of mood disorders. He asked Dr Maerz whether McNeil Laboratories had had any success in relating clinical response to blood levels.
Dr Maerz said that in many cases the blood level did not correlate totally with the clinical response. They might be contacted by a physician who had a patient on 200 mg haloperidol with no therapeutic response. Occasionally, demonstrable blood levels were also found with no clinical response. On one occasion Dr J S Howard had obtained no response at 200 mg but an excellent response at 350 mg. However such doses must be approached with caution.
Dr A J Coppen (Chairman) asked whether there was any evidence of a U-shaped curve such as that described in Scandinavia for nortryptiline. Was there an upper level at which a negative therapeutic response was obtained ?
Dr Maerz said that a catatonic patient was returning to normal if he related with demonstrative psychomotor activity. Such improvement has not yet been correlated with blood levels because of imprecise therapeutic endpoints. An approach to this was the coordinated agreement of two or more psychiatrists on optimal response, with determination of blood levels at this point. Comparison should then be made with non-responders evaluated the same way.
Dr A 0 Forsman (Gothenburg) said he believed that there was no narrow therapeutic range, if one looked only at concentrations. However, to look at the receptor response, for instance by measuring prolactin, might come closer to the clinical situation. There one was looking at the pharmacodynamic reaction and he believed that a correlate in the reaction of the brain might be found.
Dr A J Coppen said that workers in Oxford had looked at the relationship between plasma prolactin levels and therapeutic response and he did not think that they had found a very good response.
Dr Maerz said that Dr Robert Rubin in Los
Angeles demonstrated a direct linear relation between haloperidol blood levels and prolactin release. Dr Rubin did not attempt to correlate prolactin and serum haloperidol levels with therapeutic response. The study was conducted with low doses of haloperidol in normal subjects because of the possible effects otn catecholamine levels in severely anxious patients.
Dr G Silverman (Souithall) made three comments on the use of haloperidol: (1) He had found it particularly useful in quite high doses in helping families to keep demented elderly relatives at home. Lack of complications and its ability to control the patient had made it particularly effective. (2) It was well known in pharmacology that with some blocking agents one obtained first a stimulation and then a blocking. In relation to extrapyramidal side-effects, he wondered whether the effect of haloperidol was first to give a blocking and then at higher levels a stimulation of the dopadrenergic pathways. (3) In attempting to assess patients' responses he had been particularly interested in speech and speech rates. In the early stage of treating patients with haloperidol he had the impression that the drug reduced psychomotor activity in that they spoke more slowly. However, a speech pause analyser had revealed that they had been speaking at least as quickly or more quickly. The apparent slowing down had simply been due to the patients' slurring of their words. This work was soon to be published.
Mr J G Rose (Janssen) said that there had been considerable discussion and concern about the extrapyramidal symptoms which accompanied haloperidol administration. He asked the panel how they regarded the toxic hazards or risks which accompanied alternative neuroleptic therapy in the acute and chronic situation.
Dr Maerz said that toxic hazards or risks which accompany alternative neuroleptic therapy in acute and chronic situations are generally rare and develop more insidiously than extrapyramidal phenomena, which are readily reversible but appear dramatically. Autonomic side-effects, cardiovascular effects, sedation, and specific organ pathology that emerges slowly, as well as tardive dyskinesia, must be considered with chronic therapy. Recent research in New York State has projected the necessity for a complete baseline physical examination for all patients who receive long-term treatment with neuroleptic agents. These considerations, and recent legal rulings prohibiting long-term hospitalization as sole treatment for mental illnessas well as short-term (2-3 week) funding for mental illnesses, have made the physician focus on active, short-term treatment.
Dr F J Ayd (Maryland) pointed out that the incidence of extrapyramidal reactions with haloperidol was no greater than with any other potent Haloperidol: A New Profile ? neuroleptic agent. Comparative studies of the incidence of extrapyramidal reactions with fluphenazine, trifluoperazine and haloperidol showed an essentially similar incidence. If they were potent substances they would cause extrapyramidal reactions.
Neither was there any essential difference between the incidence of extrapyramidal reactions with depot neuroleptics and orally potent neuroleptics. There was simply a shift in the time of onset of such reactions. He therefore reiterated that in this regard haloperidol was no better and no worse than any of the other potent neuroleptic substances.
Dr Maerz said there was a general tendency to equate early appearance of extrapyramidal phenomena with an increased propensity to tardive dyskinesia after long-term treatment. Certainly, clinical experience did not support such a contention since the sedative neuroleptics had been incriminated in tardive dyskinesia to a greater degree than antipsychotic agents such as haloperidol. This was due to prolonged use of sedative neuroleptics and their ability to suppress extrapyramidal phenomena to a subclinical state. Unless treatment with antiparkinsonism drugs was discontinued, early developing tardive dyskinesias were not noted. On the other hand, incisive neuroleptics such as haloperidol might cause extrapyramidal phenomena early after treatment was startedin 24 hours to 2 weeksbut physicians were well aware of these phenomena and familiar with their management. Few patients with tardive dyskinesia had received only haloperidol.
Studies generally supported the contention that approximately one-third of all acute psychotic patients might not need medication beyond the acute stage. Yet many of these patients were continued on potent antipsychotic drugs for long periods. It was mandatory to stop treatment with these drugs under such circumstances. This was best accomplished by withdrawing drugs on week-ends, then every other day, and finally, by decreasing daily dosage. This tended to prevent withdrawal dyskinesias which mimicked tardive dyskinesia but were reversible within two weeks to six months. Patients should remain off medication until psychiatric symptoms reappeared.
Dr C de B White (Londoni) asked what duration was now regarded as being useful in a 'drug holiday'. Dr F J Ayd (Maryland) described to the meeting how the concept of 'drug holidays' had arisen. He had noticed with some patients who ran away from hospital and did not take their medicine, that they did not necessarily relapse. Also patients in whom therapy was discontinued for medical or surgical problems frequently failed to relapse. Initially, therefore, he started short programmes from which it was found that the holiday could last from a few days to several months, depending upon the criteria for relapse.
That these criteria might be largely subjective was shown by a comparative study in which chronic neuroleptic therapy was discontinued in two wards. In one ward 70 % of patients had been returned to medication within a month; in the other the figure was 12 %. In the former, it was the subjective discomfort on the part of the psychiatrist that accounted for the high 'relapse' rate. Relapse was often in the eye of the beholder and not the patient.
Dr J S Howard (Fresno) commented on taking the patient off antipsychotic agents when unfortunate signs of tardive dyskinesia were seen.
But he asked what alternative could be offered in treating these patients other than moving them to the chronic ward.
